Eris Lifesciences Limited — Important, 21-02-2025: Agreements

The company has secured credit facilities amounting to ₹1000 million (Cr 100) from Kotak Mahindra Bank for business purposes, which will not alter its aggregate debt level. This move reflects an effort to strengthen working capital, allowing the company to pursue operational needs without increasing overall debt. There are no specific terms or rights associated with this agreement that would impact shareholding or governance structures. While the immediate effect is neutral on the debt outlook, investors should monitor any future developments regarding the deployment of these funds and their impact on operational efficiency. Positive outlook, as this type of financing can aid growth initiatives without adding leverage.